Subcutaneous Atezolizumab Real-World Evaluation of Patient Outcomes V1
Research type
Research Study
Full title
A NON-INTERVENTIONAL, MULTICENTER, MULTICOHORT STUDY TO EVALUATE PATIENT-REPORTED SATISFACTION,EFFECTIVENESS AND SAFETY OF SUBCUTANEOUS ATEZOLIZUMAB IN PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE
IRAS ID
357073
Contact name
Head, EU/ROW Regulatory Affairs Pharmaceutical Division
Contact email
Sponsor organisation
F Hoffmann-La Roche Ltd
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
3 years, 5 months, 1 days
Research summary
This is a non-interventional, multicenter, multicohort primary data collection study.
The choice of treatment with atezolizumab SC (used according to locally approved [SmPC]) will be at the discretion of the treating physician and
independent of the patient’s participation in this study.The study aims to address the following research questions in patients with lung cancer and hepatocellular cancer treated with atezolizumab SC according to approved label in the real-world setting of routine clinical practice:
● What is the patient’s satisfaction with atezolizumab SC treatment?
● What is the HRQoL in patients treated with atezolizumab SC?
● What is the OS in patients treated with atezolizumab SC?
● How convenient is the atezolizumab SC treatment for patients?
● What are the patient’s physical and psychological impacts with atezolizumab SC
treatment?
● What is the impact on activities of daily living of patients treated with atezolizumab
SC?
● What is the perception of HCPs about the benefits (e.g. time, resources, and
convenience) of using atezolizumab SC in routine patient management?
● Where in routine practice is atezolizumab SC treatment most often administered (e.g. outpatient unit, day oncology center, hospital/academic center, homecare)
● Has there been a change in the place where atezolizumab SC is administered during
the course of treatment and what are the reasons for this?
● Are there patients whose treatment is changed from IV to atezolizumab SC and vice
versa and what are the reasons for that?REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
25/PR/0934
Date of REC Opinion
31 Jul 2025
REC opinion
Further Information Favourable Opinion